What are the differences in testing for central sleep apnea versus obstructive sleep apnea?

Diagnostic Testing Differences: Central vs Obstructive Sleep Apnea

Polysomnography (in-laboratory sleep study) is required to definitively distinguish central sleep apnea from obstructive sleep apnea, whereas home sleep apnea testing cannot reliably differentiate between these two conditions. 1

Key Diagnostic Distinction

Why PSG is Mandatory for CSA Diagnosis

• Home sleep apnea testing (HSAT) lacks the necessary sensors to distinguish central from obstructive events, as it cannot adequately measure respiratory effort 1

• Polysomnography remains the gold standard because it includes comprehensive monitoring of respiratory effort through chest and abdominal respiratory inductance plethysmography, which directly demonstrates whether breathing effort is present (obstructive) or absent (central) during apneic events 1

• The American Academy of Sleep Medicine explicitly recommends PSG over HSAT for patients with suspected central sleep apnea or conditions predisposing to CSA, including significant cardiorespiratory disease, heart failure, stroke history, chronic opioid use, or neuromuscular conditions 1

Clinical Algorithm for Test Selection

Use HSAT (Home Sleep Apnea Testing) When:

• Patient is uncomplicated with signs/symptoms suggesting moderate-to-severe OSA (excessive daytime sleepiness plus ≥2 of: habitual loud snoring, witnessed apneas/gasping, diagnosed hypertension) 1

• No risk factors for central sleep apnea are present 1

• Patient has no significant cardiorespiratory disease (heart failure, coronary artery disease, atrial fibrillation) 1

• No chronic opioid use, which commonly causes central apneas 1

• No history of stroke or neuromuscular conditions 1

Require In-Laboratory PSG When:

• Any suspicion of central sleep apnea based on clinical presentation 1

• Heart failure (CSA prevalence 5.8% in atrial fibrillation patients, 7.1% in prior MI patients) 2

• Chronic opioid medication use (strong predictor of central events) 1

• Stroke or cardiovascular disease history 1

• Neuromuscular conditions with potential respiratory muscle weakness 1

• Awake hypoventilation or suspected sleep-related hypoventilation 1

• HSAT results are negative, inconclusive, or technically inadequate but clinical suspicion remains 1

Technical Measurement Differences

What PSG Measures That HSAT Cannot:

• Respiratory effort via chest/abdominal bands (respiratory inductance plethysmography) definitively shows presence or absence of breathing effort during apneas 1, 3

• Esophageal pressure monitoring (gold standard research tool) can be added to PSG for definitive differentiation when conventional measures are equivocal 3

• Diaphragm electromyography (EMGdi) demonstrates neural respiratory drive and accurately distinguishes central from obstructive events 3

• EEG monitoring captures arousals and sleep architecture, which helps contextualize respiratory events 1

HSAT Limitations:

• Minimum sensors include only nasal pressure, oximetry, and sometimes peripheral arterial tonometry (PAT) - insufficient to determine respiratory effort 1

• Cannot distinguish central from obstructive apneas because it lacks chest/abdominal effort monitoring 1

• Conventional PSG with uncalibrated respiratory inductance plethysmography may overestimate CSA frequency by approximately one-third compared to gold-standard esophageal pressure or diaphragm EMG measurements 3

Critical Clinical Pitfalls

Common Diagnostic Errors:

• Assuming HSAT can rule out CSA - it cannot, and a negative HSAT in a patient with CSA risk factors requires follow-up PSG 1

• Relying on automatic scoring algorithms alone - raw PSG data must be manually reviewed by a board-certified sleep medicine physician to identify central events and other abnormalities 1

• Missing treatment-emergent central sleep apnea - patients initially diagnosed with OSA may develop central apneas after starting PAP therapy, requiring repeat PSG 4, 5

High-Risk Populations Requiring PSG:

• Older males have substantially higher CSA risk (age and male sex are strongest demographic predictors) 2

• Cardiovascular disease patients: myocardial infarction (adjusted OR 1.88), atrial fibrillation (adjusted OR 1.85) 2

• CSA represents only 2% of all sleep study patients but 5.5% of those with AHI ≥5, making it easily missed without proper testing 2

Management Implications

• Treatment differs fundamentally between OSA and CSA - OSA typically responds to CPAP or oral appliances, while CSA may require bilevel PAP with backup rate, adaptive servo-ventilation, oxygen, acetazolamide, or phrenic nerve stimulation 4

• Misdiagnosis leads to inappropriate treatment and potential harm (e.g., adaptive servo-ventilation is contraindicated in heart failure with reduced ejection fraction without careful monitoring) 4

• Follow-up PSG is indicated when initial treatment fails or when clinical suspicion for CSA emerges during OSA treatment 1, 4, 5